Printer Friendly

/C O R R E C T I O N -- OSTEOTECH/

 /C O R R E C T I O N -- OSTEOTECH/
 In NY016, Osteotech receives patent, moved yesterday, the first


graph, fifth line, should read "demineralized bone particles" rather than "bone parties" as originally transmitted.
 The corrected release follows:
 OSTEOTECH RECEIVES U.S. PATENT FOR A UNIQUE COATING FOR IMPLANTS
 SHREWSBURY, N.J., Nov. 11 /PRNewswire/ -- Osteotech, Inc. (NASDAQ: OSTE) announced today that the U.S. patent and trademark office has awarded the company U.S. patent No. 5,061,286 for technologies relating to the coating of non-absorbable osteoprosthetic implants. The coatings are derived from demineralized bone particles, a biomaterial that is recognized to stimulate the formation of new bone. The coatings may improve the ability of the patients' bone to grow into implanted artificial hips, knees and other devices. The patent is a result of the company's research and development activities in the field of bone healing. Further research is required to assess the clinical utility of the technology.
 Osteotech is the leading processor of human bone and bone connective tissue for transplantation, and an innovator in the development of tissue related biomaterials and pharmaceutical delivery systems for musculoskeletal surgery.
 -0- 11/12/91
 /CONTACT: Michael J. Jeffries of Osteotech, 908-542-2800/
 (OSTE) CO: Osteotech, Inc. ST: New Jersey IN: MTC SU: KD-OS -- NY001A -- 3420 11/12/91 11:25 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 12, 1991
Words:222
Previous Article:LICON INTERNATIONAL IS AWARDED OVER $1.1 MILLION WORTH OF CONTRACTS
Next Article:MOTOROLA IS SUPPLIER AND PARTNER OF URUGUAY'S FIRST CELLULAR SYSTEM
Topics:


Related Articles
OSTEOTECH RECEIVES U.S. PATENT FOR A UNIQUE COATING FOR IMPLANTS
IBM AND MULTI SOFT SIGN SOFTWARE MARKETING AGREEMENT
DCA ANNOUNCES SELECT COMM SERVER WITH PC ROUTER SUPPORT
IBM AND MULTI SOFT SIGN ADDITIONAL MARKETING AGREEMENT
IBM AND MULTI SOFT SIGN THIRD INTERNATIONAL MARKETING AGREEMENT; COVERING EUROPE, THE MIDDLE EAST AND AFRICA
CompuServe, Golden CommPass Team Up To Reach OS-2 Market
IBM Ships OS/390 2.7, Previews Future Releases.
CAI to Help Make OS/390 Secure for E-Commerce.
Patients With HIV-Associated Wasting Gain More Weight With Concentrated Form of Megestrol Acetate, Study Shows.
Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters